Abstract

Background

Brucellosis is listed as one of six priority zoonoses in Tanzania’s One Health strategic plan which highlights gaps in data needed for the surveillance and estimation of human brucellosis burdens. This study collected data on current testing practices and test results for human brucellosis in Arusha region, northern Tanzania.

Methods

Retrospective data were extracted from records at 24 health facilities in Arusha region for the period January 2012 to May 2018. Data were captured on: the test reagents used for brucellosis, procurement and testing protocols, the monthly number of patients tested for brucellosis and the monthly number testing positive. Generalised linear mixed models were used to evaluate relationships between health facility characteristics and the probability that brucellosis testing was conducted in a given month, and the proportion of individuals testing positive.

Results

Four febrile *Brucella* agglutination tests were used widely. The probability of testing for brucellosis in a given month was significantly associated with an interaction between year of testing and facility ownership. Test probability increased over time with more pronounced increases in privately owned as compared to government facilities. The proportion of individuals testing positive for brucellosis was significantly associated with facility type and district, with individuals tested in hospitals in Meru, Monduli and Ngorongoro districts more likely to test positive.
Conclusions

Febrile *Brucella* agglutination tests, known for their poor performance, were the mainstay of brucellosis testing at health facilities in northern Tanzania. The study indicates that historical data on human brucellosis in Arusha and other regions are likely to provide an inaccurate measure of true disease burden due to poor performance of the tests used and variation in testing practices. Measures to address these identified shortcomings could greatly improve quality of testing and surveillance data on brucellosis and ultimately inform prevention and control of this priority disease.

Introduction

Tanzania’s One Health strategic plan (2015–2020) highlights brucellosis as one of six high priority zoonotic diseases [1, 2]. The strategic plan identifies knowledge gaps on the incidence, testing and surveillance of brucellosis among other priority zoonoses targeted for control and elimination [1, 2]. Previous hospital and community-based febrile studies have estimated that up to 7.7% of the population in the pastoralist communities of northern Tanzania are exposed to *Brucella* [3], while 6.1% and 3.5% of acute patients from rural pastoralist and peri-urban, agro-pastoral settings respectively have been identified as confirmed brucellosis cases [4, 5]. The use of standardised protocols for testing, use of internationally recognised diagnostic tests and use of a standard case definition to generate surveillance data on human brucellosis are not currently practiced in Tanzanian health facilities [1].

In Tanzania, the guidelines for surveillance and reporting of prioritized diseases, recommend the use of the electronic, Integrated Disease Surveillance and Reporting system (IDSR) [6]. The system, which is used by health facilities to report disease case data to national surveillance systems, is designed to identify cases of priority, notifiable diseases based on the 10th version of the WHO International Statistical Classification of Diseases and Related Health Problems (ICD-10) [6–8]. The IDSR guidelines were first incorporated into the Tanzanian health system in 2001 and included 13 priority diseases. In 2011, the national IDSR guidelines were revised to include surveillance of 34 priority diseases and conditions in its second phase [9]. Although brucellosis is not a notifiable disease, it is a priority zoonosis in Tanzania, that should be reported at health facilities [6]. However, despite these goals, the IDSR system is not fully integrated into health facility information management systems, especially in rural, primary health facilities and brucellosis is currently not routinely included as a priority disease within the IDSR system [6]. The second phase of the IDSR platform is currently used in most district and referral hospitals, but in the primary health facilities paper-based facility logs are still widely used [10, 11]. The variation in testing protocols at different health facilities for the diagnosis of brucellosis also complicates utilization of existing data. Current practices often lead to misdiagnosis of brucellosis as one of a range of other common causes of febrile illness [3, 5].

The Tanzania national guidelines for brucellosis testing are based on international guidelines [6, 12, 13]. The current Tanzanian guidelines for human testing specify the screening of suspected cases with the Rose Bengal Test (RBT), with additional Rivanol precipitation testing and confirmation using either culture and isolation of bacteria or a positive molecular test result [6]. Serology tests cannot be used to confirm a brucellosis diagnosis using a single acute-stage sample nor can they differentiate the species of *Brucella* in positive samples [14]. A
number of research studies conducted in regions where higher prevalence of brucellosis is suspected have successfully applied the CDC and WHO recommended diagnostic protocols [5, 15–18]. To date, however, none of these recommended diagnostic protocols have been applied at scale for the diagnosis of human brucellosis in Tanzanian health facilities [10, 19, 20]. Instead, studies conducted in Tanzania and the East Africa region have identified a range of rapid, febrile *Brucella* agglutination tests (FBAT) that are used in health facilities to test for brucellosis [18–21]. None of these rapid tests are recommended for brucellosis diagnosis in any national or international guidelines and several studies to date have indicated poor performance of these rapid tests [18, 21, 22].

Tanzania has over 5,000 existing primary health care facilities (518 hospitals and health centers and 4,554 dispensaries) [23, 24]. The health service organization follows a pyramid structure starting at community level with primary health facilities (dispensaries and health centers), then leading to hospitals serving at the district level and finally up to referral hospitals, providing services to whole administrative regions or zones [25]. Basic health service provision is generally focused at primary health facilities in the ward, village and sub-village levels, with oversight and management coordinated at district level facilities. A hospital or health center at the district level can be designated to manage the health services within the district, and is then referred to as a designated district hospital or health center, respectively. The health information system used in primary health facilities is part of the *Mfumo wa Taarifa za Uendeshaji Huduma za Afya* (MTUHA translated as “health services information management system”) framework. The MTUHA, which is a paper-based record management system, was first introduced into health facility systems in 1993 [11]. A review of the MTUHA framework and incorporation into IDSR systems was done in 2011, leading to a new national training and implementation program in 2012 [11]. Records of patient management at each facility are generated within a health information system designed to comply with the IDSR framework. Departmental logbooks used within each facility record individual level details of patient testing and results, including brucellosis testing, where performed [11, 26]. Patient records are aggregated daily for reporting into the district health information software (DHIS) through a set of facility level log books [11]. These facility level summaries do not record brucellosis as a specific etiology of illness and instead aggregate brucellosis diagnoses among a range of diseases as “other causes of fever”. The DHIS further aggregates data into regional and referral health systems that are compiled for the Ministry of Health Community Development, Gender, Elderly and Children surveillance systems [23]. Data on brucellosis diagnoses specifically are therefore not routinely compiled or reported from the aggregated facility level summary records upwards through the current reporting system.

Previous studies conducted in Arusha region have demonstrated high prevalence of human brucellosis using the WHO and CDC recommended guidelines for diagnosis and case definitions [4, 27–29]. Higher prevalence has also been documented in previous studies within rural, pastoralist communities [17, 30, 31], which make up a large proportion of the population in Arusha region and northern Tanzania overall as compared to urban and peri-urban communities [32, 33].

This study included a survey of health facilities in Arusha region to evaluate the current practices in place for generating data on the diagnosis of human brucellosis. The study aimed to quantify the patterns in brucellosis test performance across facilities, months of the year and the proportion of patients tested who were brucellosis positive at included health facilities. The study also aimed to identify the test reagents used for diagnosis of brucellosis, their procurement and the protocols used for their performance at health facilities within Arusha region. The findings of this study provide a quantitative characterization of current brucellosis testing practices in northern Tanzania and can be used to inform future improvements in surveillance
systems for this priority disease. The findings of this study can inform policy for improved diagnosis and reporting of brucellosis, and also more general guidance on surveillance of a wide range of emerging and priority zoonoses in Tanzania as with many lower and middle income countries (LMICs) in sSA [34, 35]. Improved surveillance and reporting of priority diseases has the potential to increase health care services, public health in general and the capacity for health authorities to quickly and effectively respond to disease outbreaks [36].

Methods

Ethics and approval
The study was approved by the Kilimanjaro Christian Medical College Research Ethics and Review Committee (CRERC, Cert. 829) and the National Institute for Medical Research (NIMR/HQ/R.8c/Vol. II/1140). The study also obtained written approval from national, regional and district level authorities as well as permission to access institution level data from the respective health facility authorities, prior to collection of data. The identity of the institutions included in the study were masked for confidentiality. No individual patient level data were accessed for this study.

Study area
Data for this study were compiled over the period from September to November 2018 in the seven administrative districts of Arusha region; Arusha Urban, Arusha District Council (DC), Meru, Longido, Monduli, Karatu and Ngorongoro districts (Fig 1). Arusha Region, located in the northern zone of Tanzania, has a population mainly comprised of pastoralist and agropastoralist livestock keepers in the rural areas with a mixed agro-business urban population [32, 37].

Data collection process
To create a list of all registered health facilities certified to perform brucellosis testing, the regional health management team (RHMT) responsible for oversight in Arusha region were consulted. District health facilities designated to manage health services within each district were identified at the Arusha Regional Medical Office (RMO) by accessing the DHIS. Through collaboration with the RHMT personnel and district laboratory technologists, facilities within each district with laboratories that had been certified to conduct brucellosis testing were identified and listed. District Medical Officers (DMOs) of each district were contacted in advance of all data collection visits. Contact details for the health facilities registered and approved to conduct brucellosis testing were then obtained from the respective DMO and district laboratory technologist and all listed facilities were approached to introduce the study. An appointment was made with a management representative for each facility, by calling ahead. At least three call attempts were made to each approached facility in order to set up a visit. All facilities where phone contact was unsuccessful after three attempts were excluded from the study. At each facility visited, a brief introduction of the study objectives was presented to the respective representative authority as well as the key heads of department facilitating the data collection, lab technicians in charge and in most cases, the health secretaries of the facility to enable sharing of data from records. A structured questionnaire was applied to capture details of current brucellosis testing practices, reagent procurement systems in use and protocols used for testing brucellosis at each facility. The respondent in each case was the person responsible for collection of data on brucellosis for the relevant department including the laboratory, in- and out-
For each month in the period from January 2012 to May 2018, the following data were extracted from facility records:

- number of patients tested for brucellosis
- number of patients recorded as test positive for brucellosis

Data handling and analyses

Data were entered in Microsoft Office Excel, and all analyses performed using R [40]. For initial summaries of testing records, all months with non-missing data on the number of individuals tested for brucellosis and number positive in that month were included. Generalized linear mixed models were used to evaluate variable associations with two outcome metrics. First, the performance of any brucellosis testing (or not) for each month and the proportion of all brucellosis tested patients who were test positive in each month (including only months when testing was performed). For both models, data from one private testing laboratory were excluded. The data from this facility indicated that brucellosis testing was performed on the majority of individuals, indicating a test service provision role as compared to the testing based on clinical patient evaluations apparently performed at the other included facilities. Variables evaluated in these models included the year of data collection, month of the year, district, type of health facility and health facility ownership. For model analyses the facility type variable was simplified to two levels to differentiate health centers (designated district health centers, district health centers, health centers, private health centers and other health facilities) and hospitals (designated district hospitals, private hospitals and regional referral hospitals).
Facility ownership was also simplified to two levels to differentiate government and privately owned (including privately owned and those run by faith-based organizations) facilities. Interaction terms evaluated included a year and ownership interaction for the model of brucellosis test performance and a year and month interaction for the model of proportion testing brucellosis positive. A random effect for the health facility ID was included in both models to account for repeat observations at each facility. For the model with proportion of all brucellosis tested patients who were test positive in each month as outcome, an observation level random effect (unique for each combination of facility ID and month of data collection) was also included to account for overdispersion. For each outcome modeled, initial maximal models including interaction terms were fitted and model simplification performed using likelihood ratio tests (LRT), with a significant p value of $\leq 0.05$. Residual diagnostics for final models were performed using the ‘DHARMa’ package in R [41].

Results

Facility identification and characteristics

A total of 86 health facilities registered and approved to conduct brucellosis testing were identified and approached within Arusha region. Of these 24 (27.9%) were visited for data collection for this study. Of the remaining facilities, 51 (59.3%) could not be reached after three attempts and 10 (11.6%) were contacted but declined participation in the study stating grounds that they did not perform brucellosis testing. A single facility (1.2%) withdrew after initial enrollment in the study (Fig 2). The characteristics of the health facilities approached for the study and of those that contributed data are shown in Table 1. Additional details for all facilities contributing data are also given in S1 Table. Lower levels of participation in the study are observed for facilities in Arusha DC and Arusha Urban districts as compared to other districts. Participation was also less likely for health centers as compared to hospitals.

Monthly brucellosis testing data

Over the 77 months of the data compilation period (from January 2012 to May 2018 inclusive), 1362 monthly entries with complete data on brucellosis testing and results were extracted for 23 facilities (one private testing laboratory excluded) from the MTUHA departmental
logbooks, with 409 months missing data. Only two of 23 facilities (8.7%) had contributed complete data on monthly testing for all 77 months of the study period. The 23 included facilities contributed a mean of 59 months data with a range of 16 to 77 months. This translates as overall data completeness of 76.9% for all included facilities and ranging 20.8–100% for individual facilities. Of the 1362 monthly facility entries, 776 (57.0%) entries were for months and facilities where testing of one or more persons for brucellosis was recorded. The data completeness for each year of the survey period is shown in S1 Fig. The compiled data include records of 85,013 brucellosis tests, of which 14,481 (17.0%) were test positive.

The final generalized linear mixed model with the outcome of any brucellosis testing (or not) for each month included a significant interaction between facility ownership and year (Table 2, Fig 3). The coefficients for the year variable main effect indicate increased probability of testing over time with a clear increase from 2012 to 2015 and then more stable probability in following years. The influence of this year effect on test probability was variable between private and government owned facilities however, with more pronounced increases (relative to 2012) in test probability for private compared to government owned facilities and variable effects over different years. The predicted probability of brucellosis testing by year and facility ownership is illustrated in Fig 3. The performance of testing or not in each month of the survey period is also shown in Fig 4. A random effect variable for the facility ID was included in the model and the intra-cluster correlation was 0.88. The marginal $R^2$ for this model was 33.7% and the conditional $R^2$ was 88.4% (Table 2).

The mean proportion of individuals tested for brucellosis who had a positive result recorded ranged from 0 to 100 with a mean of 21.0% (95% CI = 0–36.2). The final generalized linear mixed model with the outcome of proportion of individuals testing positive for brucellosis for each month (including only records for months where some brucellosis testing was performed) included two variables that were significantly associated with the proportion positive (Table 3). First, facility type, with higher proportions testing positive in hospitals compared to health centers. Second, the district with a significantly higher proportion of individuals testing positive in Meru and marginally higher proportions positive in Monduli and Ngorongoro as compared to the reference level of Arusha DC. Random effect variables for the facility ID and an observation level random effect (for facility month combination) were included in the model and the intra-cluster correlations were 0.23 and 0.59 respectively. The marginal $R^2$ for this model was 9.4% and the conditional $R^2$ was 14.4% (Table 2).

### Table 1. Summary of the district location and facility type of all health facilities (n = 86) approached for participation in this study and the subset (n = 24) that contributed data.

| Variable   | N total facilities approached | N (%) facilities contributing data |
|------------|------------------------------|-----------------------------------|
| District   |                              |                                   |
| Arusha DC  | 18                           | 4 (22.2%)                         |
| Arusha Urban | 41                        | 7 (17.1%)                         |
| Karatu     | 6                            | 3 (50.0%)                         |
| Longido    | 4                            | 1 (25.0%)                         |
| Meru       | 7                            | 4 (57.1%)                         |
| Monduli    | 5                            | 2 (40.0%)                         |
| Ngorongoro | 5                            | 3 (60.0%)                         |
| Facility type |                     |                                   |
| Hospital   | 12                           | 8 (66.6%)                         |
| Health centre | 74                      | 16 (21.6%)                        |
| TOTAL      | 86                           | 24 (27.9%)                        |

https://doi.org/10.1371/journal.pone.0265612.t001
Testing reagents and procedures used in the diagnosis of brucellosis

A total of 21 (87.5%) of the 24 facilities included in this study reported conducting brucellosis testing at the time of the study visit (September to November 2018). Of these facilities, 18 (85.7%) had brucellosis testing reagents in the laboratories at the time of the study. All 18 participating facilities used a type of rapid Febrile Brucella Antigen Test (FBAT) at the time of the study (Table 4). All 24 study facilities reported previous use of at least one of the named FBAT kits: Arkay, Eurocell, Fortress or Genuine Biosystems. Procurement of test reagents was done

---

**Testing reagents and procedures used in the diagnosis of brucellosis**

A total of 21 (87.5%) of the 24 facilities included in this study reported conducting brucellosis testing at the time of the study visit (September to November 2018). Of these facilities, 18 (85.7%) had brucellosis testing reagents in the laboratories at the time of the study. All 18 participating facilities used a type of rapid Febrile Brucella Antigen Test (FBAT) at the time of the study (Table 4). All 24 study facilities reported previous use of at least one of the named FBAT kits: Arkay, Eurocell, Fortress or Genuine Biosystems. Procurement of test reagents was done

---

**Table 2. Multivariable model of variables associated with brucellosis test performance by month at health facilities in Arusha region (n = 1300 monthly observations from 23 facilities).**

| Variable                  | Levels          | Odds Ratio | 95% CI      | p-value | LRT χ² | p-value |
|---------------------------|-----------------|------------|-------------|---------|--------|---------|
| Intercept                 |                 | 0.02       | 0.00–0.034  | <0.001  | -      | -       |
| Year                      | 2012 (ref)      | -          | -           | -       | -      | -       |
|                           | 2013            | 8.91       | 1.29–61.64  | 0.027   | -      | -       |
|                           | 2014            | 8.32       | 1.22–56.59  | 0.030   | -      | -       |
|                           | 2015            | 19.96      | 2.94–135.63 | 0.002   | -      | -       |
|                           | 2016            | 29.92      | 4.40–203.65 | 0.001   | -      | -       |
|                           | 2017            | 17.47      | 2.58–118.43 | 0.003   | -      | -       |
|                           | 2018 January to May | 24.85 | 3.35–184.40 | 0.002   | -      | -       |
| Facility ownership        | Government (ref)| -          | -           | -       | -      | -       |
|                           | Private         | 9.45       | 0.16–550.47 | 0.279   | -      | -       |
| Year × Facility own       | 2013 × Private  | 1.03       | 0.08–13.58  | 0.979   | 46.17  | <0.001  |
|                           | 2014 × Private  | 63.52      | 3.39–1191.52| 0.006   | -      | -       |
|                           | 2015 × Private  | 56.64      | 2.94–1085.85| 0.007   | -      | -       |
|                           | 2016 × Private  | 12.66      | 0.69–232.22 | 0.087   | -      | -       |
|                           | 2017 × Private  | 147.24     | 7.31–2966.13| 0.001   | -      | -       |
|                           | 2018 × Private  | 19.74      | 0.91–426.19 | 0.057   | -      | -       |

CI - confidence interval of estimate; LRT – Likelihood ratio test; χ² – Chi square; Random Effects: σ² = 3.29; Facility ID = 15.59

https://doi.org/10.1371/journal.pone.0265612.t002

**Fig 3. Predicted probabilities of brucellosis testing per month by year and facility ownership type.** The red dots indicate point estimates with confidence intervals for government owned facilities. Blue dots indicate point estimates with confidence intervals for privately owned health facilities.

https://doi.org/10.1371/journal.pone.0265612.g003
entirely through private suppliers in Arusha Urban district. All of the surveyed facilities reported purchasing brucellosis tests from one of two private distributors. All the facilities included in the study used test results to define or inform case definitions for brucellosis. A total of five of 18 facilities (20.8%) also responded that diagnosis of brucellosis was regularly based on clinician judgment (case presentation and history taking), particularly when there were shortages of testing reagent. One (4.2%) of the 24 health facilities reported previous use of the Rose Bengal Test, although it was not in use at the time of the study (Table 4). Five (27.8%) of the 18 facilities with test reagents on premises reported using controls in performance of their routine test runs, or as a regular quality assurance measure for reagents used. The facilities using controls for testing used previously identified “positive sera” in two of five (40%), or kit provided control sera in three of five facilities (60%) as test controls. In the 18 health facility department logs where brucellosis testing was conducted brucellosis was recorded as “Positive” or “Negative” for 15 (62.5%) facilities and as *Brucella abortus*, *melitensis* for three (12.5%) facilities.

**Table 3. Multivariable model of variables associated with proportion of individuals testing positive for brucellosis at health facilities in Arusha region (n = 776 monthly observations from 20 facilities).**

| Variable | Levels                  | Odds Ratios | 95% CI        | p-value  | LRT $\chi^2$ | p-value |
|----------|-------------------------|-------------|---------------|----------|--------------|---------|
| (Intercept) | 0.11                    | 0.05 – 0.28 | <0.001        |          |              |         |
| District  | Arusha DC (ref)         | -           | -             | -        | 14.49        | 0.025   |
| Arusha Urban | 1.04                    | 0.42 – 2.60 | 0.930         |          |              |         |
| Karatu    | 0.83                    | 0.30 – 2.26 | 0.713         |          |              |         |
| Longido   | 2.08                    | 0.23 – 18.78| 0.516         |          |              |         |
| Meru      | 3.59                    | 1.14 – 11.29| 0.029         |          |              |         |
| Monduli   | 3.49                    | 0.93 – 13.04| 0.063         |          |              |         |
| Ngorongoro | 2.62                    | 0.98 – 7.00 | 0.056         |          |              |         |
| Facility type | Health center (ref)     | -           | -             | -        | 4.56         | 0.033   |
| Hospital  | 1.89                    | 1.07 – 3.33 | 0.027         |          |              |         |

CI - confidence Interval of estimate; LRT–Likelihood ratio test, $\chi^2$ –Chi square; Random Effects: $\sigma^2 = 3.84$; Facility-month = 0.55; Facility ID = 0.20.

https://doi.org/10.1371/journal.pone.0265612.t003
Discussion

In this study we observed that the performance of brucellosis testing or not in each month at health facilities was significantly associated with an interaction between the year of data collection and facility ownership. All participating facilities used the FBAT kits for testing, procured from private distributors, and only one facility reported ever using the Rose Bengal Test. The proportion of individuals testing positive for brucellosis for each month was significantly associated with the district and classification of the facility where testing was done.

This study found that 80.6% of the health facilities included in this study had reagents or a kit for brucellosis testing at the time of the study. Four FBAT kits were being used in health facilities (Table 3), with the Eurocell (80.6%) the most commonly used at the time of the study and previously reported to have been used at 47.6% participating facilities during the entire data extraction period. None of the health facilities included in the study used the Rose Bengal Test at the time of the survey, although one (4.2%) reported its previous use for diagnosis of brucellosis during the full study period (Table 3). Three of the FBAT test kits commonly used in health facilities across Arusha region have documented poor performance in testing for brucellosis using patient samples from this region [18, 21]. It was also observed that most facilities (72.2%) did not ensure quality of testing by use of controls, and 40% of those that did reported using example patient sera as positive and negative controls rather than standards with validated results. Records in 12.5% of facilities reported brucellosis test results as *B. abortus* or *B. melitensis*, misrepresenting the ability to distinguish the species of *Brucella* using serology tests. This fact and the observed widespread use of FBAT kits raises concerns about quality of current practice for brucellosis testing. The FBAT tests have been shown to have low specificity and poor diagnostic accuracy [18, 21] in testing for brucellosis. This not only points to high rates of patient misdiagnosis, but also contributes to a likely inaccurate and misleading picture of the epidemiology and overall clinical burden of brucellosis [13, 21, 42]. All the FBAT kits identified in this study were purchased through private suppliers and distributors of reagents. Commercial procurement of reagents through decentralized sources leads to variation in price and availability of reagents for brucellosis testing also observed in this study (S1 Table) [22, 43, 44].

In 2011 the Tanzanian IDSR platform that involves the use of the paper-based log books was reviewed and found to be underutilized as an effective data collection tool [11, 23, 26]. As a result, the new guidelines implemented in 2012, involved training of key health facility staff and improved supervision of data reporting. The completeness of data extracted from facility log-books on brucellosis testing was higher in all years after 2012 (Table 1, S1 Fig). The regression analysis showed that the performance of brucellosis testing (or not) in each month was significantly associated with the year in which testing was done and the ownership of the health facility, with an interaction between these two variables. The probability of testing
increased over time and in private as compared to government owned health facilities, but with a less pronounced and more variable increase in probability of testing over time in government as compared to privately owned facilities (Table 5, Fig 3). Both the observed increase in data completeness and proportion of months in which brucellosis testing was performed later in the data collection period could be associated with better reporting of testing at facilities likely indicating a beneficial effect of the update IDSR guidelines and training provided from 2012 onwards. This finding indicates the benefits of the efforts made to provide training, increase awareness and ensure systematic aggregation of data from health facilities to improve data quantity compiled for health facilities [11].

The observation that testing for brucellosis was more likely in private compared to government owned health facilities for several years of the survey period could be because private health facilities are typically better resourced than government facilities and thus equipped to introduce and sustain more brucellosis testing. It could also reflect the fact that services provided in private health facilities are more patient driven, indicating demand-driven brucellosis testing as has been observed in other studies [10, 45, 46]. It is important to recognize that the clinical rationale for the performance of brucellosis testing (or not) is likely to have been variable across the temporal and spatial intervals captured in this survey and that this underlying but un-observed variation in the clinical ‘need’ for brucellosis testing in each month and location is likely to also contribute to the variation observed in these data.

The study found a mean proportion of 21% patients that had a brucellosis test were classified as positive. A previous study among high-risk abattoir workers in Tanga Region using the Rose Bengal Test reported a prevalence of up to 19.5% [47]. This mean 21% reported in Arusha Region over the seven-year study period is slightly higher than the focused abattoir workers’ study, probably due to the higher test positivity reported with most FBAT kits in Arusha health facilities compared to the Rose Bengal Test used in the Tanga study [18, 22]. The higher prevalence observed in this dataset as compared to that recorded with the RBT in the targeted, high-

### Table 5. Characteristics of monthly level data from 24 health facilities over all months of observation (n = 1362 months of observation).

| Variable               | Category       | Monthly observations (N = 1362) n (%) |
|------------------------|----------------|--------------------------------------|
| Year                   |                |                                      |
| 2012                   | 65 (4.8)       |                                      |
| 2013                   | 171 (12.6)     |                                      |
| 2014                   | 219 (16.1)     |                                      |
| 2015                   | 255 (18.7)     |                                      |
| 2016                   | 263 (19.3)     |                                      |
| 2017                   | 275 (20.2)     |                                      |
| 2018 January to May    | 114 (8.4)      |                                      |
| District               |                |                                      |
| Arusha DC              | 190 (14.0)     |                                      |
| Arusha Urban           | 423 (31.1)     |                                      |
| Karatu                 | 209 (15.3)     |                                      |
| Longido                | 62 (4.6)       |                                      |
| Meru                   | 228 (16.7)     |                                      |
| Monduli                | 55 (4.0)       |                                      |
| Ngorongoro             | 195 (14.3)     |                                      |
| Facility type          |                |                                      |
| Hospital               | 452 (33.2)     |                                      |
| Health center          | 910 (66.8)     |                                      |
| Facility ownership     |                |                                      |
| Government             | 640 (47.0)     |                                      |
| Private                | 722 (53.0)     |                                      |

[https://doi.org/10.1371/journal.pone.0265612.t005](https://doi.org/10.1371/journal.pone.0265612.t005)
risk group prevalence reported among slaughterhouse workers does not seem epidemiologically plausible.

The proportion of patients testing positive for brucellosis was significantly associated with the classification of the facility with a higher probability of testing positive for brucellosis in hospitals as compared to health centers (Table 2). This association could be due to the referral system of patients that lead to complicated cases (including probable brucellosis presentations) being seen in hospitals as compared to health centers and thus potentially representing a higher proportion of the tested patient population [25]. Brucellosis typically presents with non-specific symptoms and cases are often misdiagnosed as other causes of illness. Cases are therefore more likely to be defined as brucellosis after numerous visits to health facilities, including upward referral to hospitals. Patients tested in Meru district were significantly more likely to get a positive result compared to Arusha DC. Testing in Monduli and Ngorongoro districts was associated with marginally significant increased test positivity as compared to the reference level of Arusha DC. The populations in these three districts are comprised of large proportions of pastoralist communities [33], who experience increased exposure to a range of zoonotic pathogens, including brucellosis. The likely higher true prevalence of brucellosis in Monduli and Ngorongoro districts is indicated by previous reports [10, 29, 31]. However, the observed association with the district could also be explained by a greater experience of clinicians in these areas with brucellosis and as a result, the application of more stringent criteria for brucellosis testing, only testing patients with high clinical suspicion for brucellosis.

Improved awareness and knowledge of brucellosis presentations among healthcare workers, including clinical history taking and evaluation of known risk factors in patients [15, 17, 45, 48–50] have been shown to increase the accuracy of diagnosing brucellosis in cases and non-cases, even with tests shown to have low specificity and diagnostic accuracy [12, 42]. In this study, although all facilities reported relying on test results to inform patient diagnoses, 20.8% of facilities reported frequently relying on clinical diagnoses for brucellosis, especially in scenarios when laboratory testing was hampered, mostly due to lack of test reagents (S1 Table). Overall, our findings highlight areas for improvement in diagnosis and data generation on brucellosis through the use of improved diagnostic tests and the use of consistent case definitions (e.g. including both test results and clinical diagnoses for brucellosis).

This study had a number of limitations; first, the low proportion of facilities that took part in the study, with lower proportions of health centers and facilities from Arusha Urban and Arusha DC districts participating. Approximately 70% of the 86 facilities that were identified to have brucellosis testing capacity either declined to take part in the study or were not reachable. This limits the inference that can be made from study findings. We are therefore not able to investigate the influence of test kit on proportion testing positive.

The results of this study help to identify key areas for improvement to ensure future adherence with Tanzanian national brucellosis surveillance and control guidelines in health facilities. Updates to current practice such as uniform use of the RBT for testing, using standardized protocols and reliable, centralized supply are critical to achieve improved diagnosis of brucellosis in Tanzania [18, 51, 52]. The national medical stores department would be an ideal organization to regulate and sustain the supply of approved testing reagents, including the Rose Bengal Test for brucellosis [44, 53, 54]. The implementation of the IDSR in health facilities would also provide a platform for the standardized reporting of brucellosis cases, potentially leading to the improved amount and quality of data to inform on disease burden. These strategies would eventually improve the aggregation of brucellosis data.
Conclusions
This study characterizes brucellosis testing practices at health facilities in Arusha region over a retrospective period from January 2012 to May 2018. The performance of brucellosis testing was more likely to be observed after 2012 and at private health facilities compared to government owned, while test positivity was higher in hospital class facilities and particularly agro-pastoral community districts. Centralized sourcing of test reagents could potentially address variations in access to and prices of recommended reagents in effect reducing variations in probability of testing health facilities. The tests reported in use were all FBATs with known poor performance. Among the health facilities that had test reagents on site and reported testing for brucellosis, different reagents and protocols for testing of brucellosis were observed. The systematic use of the recommended Rose Bengal Test for brucellosis, specific recording and its reporting from primary health centers would provide more accurate disease burden data enforcing public health strategies for improved control and management of brucellosis and other priority zoonoses in health facilities. The lessons learned from this study could apply to surveillance and control programs for various diseases in Tanzania and equally apply to national and healthcare systems in many similar LMICs.

Supporting information
S1 Fig. Graph showing data completeness for the 23 facilities contributing data over the seven years of the data collection period. Data completeness is calculated assuming that all facilities operated for the full study period and accounts for the fact that only five months of data were included for 2018.

S1 Table. Characteristics of facilities included in the study from January 2011 to May 2018 inclusive (n = 24 facilities). CI- Confidence interval.

Acknowledgments
We would like to thank the Regional Medical Office and Health Management Team of Arusha Region for the guidance and support in the conduct of this study. The management and staff of the health facilities included in this study that facilitated the data collection process from the facility logbooks.

Author Contributions
Conceptualization: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Coletha Mathew, Richard B. Yapi, Christopher Julius Kasanga, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

Data curation: AbdulHamid Settenda Lukambagire, Damas Davis Shayo, Jo E. B. Halliday.

Formal analysis: AbdulHamid Settenda Lukambagire, Coletha Mathew, Richard B. Yapi, Jo E. B. Halliday.

Funding acquisition: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Coletha Mathew, Richard B. Yapi, Christopher Julius Kasanga, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.
Investigation: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Damas Davis Shayo, Richard B. Yapi, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

Methodology: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Damas Davis Shayo, Coletha Mathew, Christopher Julius Kasanga, Blandina Theophile Mmbaga, Jo E. B. Halliday.

Project administration: Gabriel Mkulima Shirima, Damas Davis Shayo, Coletha Mathew, Richard B. Yapi, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

Resources: Christopher Julius Kasanga, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

Supervision: Gabriel Mkulima Shirima, Christopher Julius Kasanga, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

Validation: Jo E. B. Halliday.

Visualization: AbdulHamid Settenda Lukambagire, Jo E. B. Halliday.

Writing – original draft: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Blandina Theophile Mmbaga, Jo E. B. Halliday.

Writing – review & editing: AbdulHamid Settenda Lukambagire, Gabriel Mkulima Shirima, Damas Davis Shayo, Coletha Mathew, Richard B. Yapi, Christopher Julius Kasanga, Blandina Theophile Mmbaga, Rudovick Reuben Kazwala, Jo E. B. Halliday.

References
1. The United Republic of Tanzania (URT). National Strategy for Prevention and Control of Brucellosis in Humans and Animals 2018–2023. Prime Minist Off. 2018. https://doi.org/10.1111/fcre.12333
2. United Republic of Tanzania (URT), United States Department of Defense (DoD), Defense Threat Reduction Agency (DTRA), Cooperative Threat Reduction (CTR), Cooperative Biological Engagement Program (CBEP). The United Republic of Tanzania One Health Strategic Plan 2015–2020. Dar es Salaam; 2015. Available: http://www.tzdpg.or.tz/fileadmin/documents/dpg_internal/dpg_working_groups_clusters/clusters_health/Key_Sector Documents/Tanzania_Key_Health_Documents/FINAL_URT_One_Health_Strategy_Plan_20151021.pdf
3. Crump JA, Morrissey AB, Nicholson WL, Massung RF, Stoddard RA, Galloway RL, et al. Etiology of Severe Non-malaria Febrile Illness in Northern Tanzania: A Prospective Cohort Study. PLoS Negl Trop Dis. 2013;7. https://doi.org/10.1371/journal.pntd.0002324 PMID: 23875053
4. Bodenham FR, Lukambagire SA, Ashford R, Buza JJ, Cash-Goldwasser S, Crump AJ, et al. Prevalence and speciation of acute brucellosis in febrile patients from a pastoralist community of Tanzania. Sci Rep. 2020; 10: 1–10. https://doi.org/10.1038/s41598-019-56847-4 PMID: 31913322
5. Bouley AJ, Biggs HM, Stoddard RA, Morrissey AB, Bartlett JA, Afwamba IA, et al. Brucellosis among hospitalized febrile patients in northern Tanzania. Am J Trop Med Hyg. 2012; 87: 1105–1111. https://doi.org/10.4269/ajtmh.2012.12-0327 PMID: 23091197
6. United Republic of Tanzania(URT), Guidelines for Surveillance of Prioritized Zoonotic Diseases for Human and Animal Health in the United Republic of Tanzania. Gov Rep. Dar es Salaam; 2018.
7. Rumisha SF, Mboera LE, Senkoro KP, Gueye D, Mmbuji PK. Monitoring and evaluation of integrated disease surveillance and response in selected districts in Tanzania. Tanzan Health Res Bull. 2007; 9: 1–11. https://doi.org/10.4314/thr.v9i1.14286 PMID: 17547094
8. Wu TSJ, Kagoli M, Kaasbøll JJ, Bjune GA. Integrated disease surveillance and response (IDSR) in Malawi: Implementation gaps and challenges for timely alert. PLoS One. 2018; 13: 1–19. https://doi.org/10.1371/journal.pone.0200858 PMID: 30496177
9. Nkowane BM. Streamlining and strengthening the Disease Surveillance System in Tanzania: Disease Surveillance System review, asset mapping, gap analysis, and proposal of strategies for streamlining
and strengthening disease surveillance. 2019. Available: https://pdf.usaid.gov/pdf_docs/PA00TKWC.pdf.

10. Nonga HE, Mwakapeje ER. Trends of human brucellosis in pastoralist communities based on hospital records during 2013–2016 in Ngorongoro District, Tanzania. Tanzania Vet J. 2017; 32: 34–40. Available: http://www.suaire.sua.ac.tz:8080/xmlui/bitstream/handle/123456789/2536/NongaandMwakapeje.pdf?sequence=1&isAllowed=y.

11. Wilms MC, Mbembela O, Prytherch H, Hellmold P, Kuelker R. An in-depth, exploratory assessment of the implementation of the National Health Information System at a district level hospital in Tanzania. BMC Health Serv Res. 2014; 14: 1–14. https://doi.org/10.1186/1472-6963-14-1 PMID: 24382312

12. Corbel MJ, Food and Agriculture Organization of the United Nations, World Health Organization, World Organisation for Animal Health. Brucellosis in Humans and Animals. Corbel M, Elberg S, Cosivi O, editors. World Health Organization. Geneva: WHO Press; 2006. Available: https://apps.who.int/iris/handle/10665/43597.

13. Center for Disease Control and Prevention. Brucellosis Reference Guide: Exposures, Testing and Prevention. 2017; 1–35. Available: https://www.cdc.gov/brucellosis/pdf/brucellosis-reference-guide.pdf.

14. Alton GG, Jones LM, Pietz DE. Laboratory techniques in brucellosis. Monograph series. World Health Organization. 1975. pp. 1–163. Available: https://apps.who.int/iris/bitstream/handle/10665/38676/WHO_MONO_55_part2.pdf. PMID: 812265

15. Rubach PM, Halliday JEB, Cleaveland S, Crump AJ. Brucellosis in low-income and middle-income countries. Curr Opin Infect Dis. 2014; 26: 404–412. https://doi.org/10.1097/QCO.0b013e3283638104 PMID: 23963260

16. Carugati M, Biggs HM, Maze MJ, Stoddard RA, Cash-Goldwasser S, Hertz JT, et al. Incidence of human brucellosis in the Kilimanjaro Region of Tanzania in the periods 2007–2008 and 2012–2014. Trans R Soc Trop Med Hyg. 2018; 112: 136–143. https://doi.org/10.1093/trstmh/try033 PMID: 29697848

17. Cash-Goldwasser S, Maze MJ, Rubach MP, Biggs HM, Stoddard RA, Sharples KJ, et al. Risk factors for human brucellosis in northern Tanzania. Am J Trop Med Hyg. 2017; 19: 135–140. https://doi.org/10.4269/ajtmh.17-0125 PMID: 29231152

18. Lukambagire SA, Mendes JÁ, Bodenham FR, McGiven AJ, Mkenda AN, Mathew C, et al. Performance characteristics and costs of serological tests for brucellosis in a pastoralist community of northern Tanzania. Nat Sci Reports. 2021; 11: 1–11. https://doi.org/10.1038/s41598-021-82906-w PMID: 33750848

19. Mngumi EB, Mirambo MM, Wilson S, Mishana SE. Predictors of specific anti-Brucella antibodies among humans in agro-pastoral communities in Sengerema district, Mwanza, Tanzania: The need for public awareness. Trop Med Health. 2016; 44. https://doi.org/10.1186/s41182-016-0034-5 PMID: 27857610

20. Orsel K, Ho J, Hatfield J, Manyama M, Ribble C, Van Der Meer F. Brucellosis serology as an alternative diagnostic test for patients with malaria-like symptoms. Tanzan J Health Res. 2015; 17: 1–10. https://doi.org/10.4314/thrb.v17i4.2

21. de Gianville WA, Conde-Álvarez R, Moriyón I, Njeru J, Díaz R, Cook EAj, et al. Poor performance of the rapid test for human brucellosis in health facilities in Kenya. PLoS Negl Trop Dis. 2017; 11: 1–15. https://doi.org/10.1371/journal.pntd.0005508 PMID: 28388625

22. Alumasa L, Thomas FL, Amany F, Njorge SM, Moriyón I, Makhandia J, et al. Hospital-based evidence on cost-effectiveness of brucellosis diagnostic tests and treatment in Kenyan hospitals. PLoS Negl Trop Dis. 2021; 891: 1–19. https://doi.org/10.1371/journal.pntd.0008977 PMID: 33411798

23. Kapolongwe NA, Meara JG, Kengia JT, Sonda Y, Gwajima D, Alidina S, et al. Development and upgrading of public primary healthcare facilities with essential surgical services infrastructure: A strategy towards achieving universal health coverage in Tanzania. BMC Health Serv Res. 2020; 20: 1–14. https://doi.org/10.1186/s12913-020-05057-2 PMID: 32183797

24. Ramsey K, Hingora A, Kante M, Jackson E, Exavery A, Pemba S, et al. The Tanzania Connect Project: A cluster-randomized trial of the child survival impact of adding paid community health workers to an existing facility-focused health system. BMC Health Serv Res. 2013; 13: S6. https://doi.org/10.1186/1472-6963-13-S2-S6 PMID: 23819587

25. Nicks BA, Sewe HR, Juma AM, Reynolds TA. The state of emergency medicine in the United Republic of Tanzania. African J Emerg Med. 2012; 2: 97–102. https://doi.org/10.1016/j.ajem.2012.06.002

26. Mahundi MH, Chaula BH, Igira F. Appreciating local variations in standardising health care data collection processes and tools: A case of health management information system in Tanzania. E J Info Sys Dev Ctries. 2018; 2: 1–11. https://doi.org/10.1002/isd2.12031

27. Makuia R, Majigo M V, Biwé GM, Kibwana U, Mirambo MM, Joachim A. Seroprevalence of Brucella infection and associated factors among pregnant women receiving antenatal care around human, wildlife and livestock interface in Ngorongoro ecosystem, Northern Tanzania. A cross-sectional study. BMC Infect Dis. 2020; 20: 1–7. https://doi.org/10.1186/s12879-020-4873-7 PMID: 32070308
28. Kunda JS. The epidemiology of human brucellosis in the context of zoonotic diseases in Tanzania. University of Edinburgh. 2005. https://doi.org/1842/29840
29. Gabriel SM. The epidemiology of brucellosis in animals and humans in Arusha and Manyara regions of Tanzania. The University of Glasgow. The University of Glasgow. 2005. Available: http://theses.gla.ac.uk/4826/1/2005shirimaphd.pdf.
30. Shirima GM, Fitzpatrick J, Kunda JS, Mfinanga GS, Kazwala RR, Kambarage DM, et al. The role of livestock keeping in human brucellosis trends in livestock keeping communities in Tanzania. Tanzan J Health Res. 2010. https://doi.org/10.4314/thrb.v12i3.51261
31. John K, Fitzpatrick J, French N, Kazwala R, Kambarage D, Mfinanga GS, et al. Quantifying risk factors for human brucellosis in Rural Northern Tanzania. PLoS One. 2010;5. https://doi.org/10.1371/journal.pone.0009968 PMID: 20376363
32. Pastoralists Indigenous Non-Governmental Organization’s Forum (PINGO). Socio-Economic Contributions of Pastoralism as a Livelihood System in Tanzania: Case of Selected Pastoral Districts in Arusha, Manyara and Dar Es Salaam Regions. Arusha, Tanzania; 2016. doi:https://www.pingosforum.or.tz/index.php/about-us/reports/studies/53-socio-economic-study/file.
33. Ministry of Health, Community Development, Gender, Elderly and Children (MoHCDGEC) [Tanzania Mainland], Ministry of Health (MoH) Z, (NBS) NB of S, (OGCS) O of the CGS, ICF. Tanzania Demographic and Health Survey and Malaria Indicator Survey (TDHS-MIS) 2015–16. Dar es Salaam, Tanzania and Rockville, Maryland, USA; 2016. Available: https://dhsprogram.com/pubs/pdf/fr321/fr321.pdf.
34. Munyua P, Osoro E, Hunsperger E, Ngere I, Muturi M, Mwatondo A, et al. High incidence of human brucellosis in a rural Pastoralist community in Kenya, 2015. PLoS Negl Trop Dis. 2021; 15: e0009049. https://doi.org/10.1371/journal.pntd.0009049 PMID: 33524052
35. Munyua P, Bitek A, Osoro E, Pieracci EG, Muema J, Mwatondo A, et al. Prioritization of zoonotic diseases in Kenya, 2015. PLoS One. 2016; 11: 1–11. https://doi.org/10.1371/journal.pone.0161576 PMID: 27557120
36. Nkowane BM. Streamlining and strengthening the Disease Surveillance System in Tanzania: Disease Surveillance System review, asset mapping, gap analysis, and proposal of strategies for streamlining and strengthening disease surveillance. Dar es Salaam; 2019. Available: https://pdf.usaid.gov/pdf_docs/PA00TKWC.pdf.
37. Wolff M, Greenberg P. Antigen-specific activation and cytokine-facilitated expansion of naive, human CD8+ T cells. Nat Protoc. 2015; 9: 950–966. https://doi.org/10.1038/nprot.2014.064.Antigen-specific
38. Tennenkes M. tmap: Thematic Maps in R. J Stat Softw. 2018; 84: 1–39. https://doi.org/10.18637/jss.v084.i01 PMID: 30450020
39. National Bureau of Statistics T. Tanzania National Bureau of Statistics 2012 housing census. In: 2012 [Internet]. 2012. Available: https://www.nbs.go.tz/index.php/en/census-surveys/population-and-housing-census/173-2012-phc-shapelifiles-level-three.
40. R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020. Available: https://www.r-project.org/.
41. Hartig F, Lohse L. Package “DHARMa” Title Residual Diagnostics for Hierarchical (Multi-Level / Mixed) Regression Models. Regensburg, Germany: University of Regensburg; 2021. pp. 1–61. Available: http://florianhartig.github.io/DHARMa/.
42. Al Dahouk S, Noëcker K. Implications of laboratory diagnosis on brucellosis therapy. Expert Rev Anti Infect Ther. 2011; 9: 833–845. https://doi.org/10.1586/eri.11.55 PMID: 21810055
43. Schroeder LF, Elbireer A, Jackson JB, Amukele TK. Laboratory diagnostics market in East Africa: A survey of test types, test availability, and test prices in Kampala, Uganda. PLoS One. 2015;10. https://doi.org/10.1371/journal.pone.0134578 PMID: 26226183
44. URT PMI, USAID, Centers for Disease Control and Prevention (CDC). President’s Malaria Initiative Plan FY 2018. Dar es Salaam; 2018.
45. Dieckhaus KD, Kyebambe PS. Human Brucellosis in Rural Uganda: Clinical Manifestations, Diagnosis, and Comorbidities at Kabale Regional Referral Hospital, Kabale, Uganda. Open Forum Infect Dis. 2017; 4: 1–6. https://doi.org/10.1093/ofid/ofx237 PMID: 29255733
46. Kansinsime C, Rutebemberwa E, Mugisha A, Mugisha S, Asimwe BB, Rwego I, et al. Determinants of patients’ choice of provider in accessing brucellosis care among pastoral communities adjacent to Lake Mburo National Park in Kiruhura District, Uganda. PLoS One. 2014; 9: 1–9. https://doi.org/10.1371/journal.pone.0105276 PMID: 25133548
47. Swai ES, Schoonman L. Human Brucellosis: Seroprevalence and Risk Factors Related to High Risk Occupational Groups in Tanga Municipality, Tanzania. Zoonoses Public Health. 2009; 56: 183–187. https://doi.org/10.1111/j.1863-2378.2008.01175.x PMID: 18811674
48. Sekamatte M, Krishnasamy V, Bulage L, Kihembo C, Nantima N, Monje F, et al. Multisectoral prioritization of zoonotic diseases in Uganda, 2017: A One Health perspective. PLoS One. 2018; 13: 1–11. https://doi.org/10.1371/journal.pone.0196799 PMID: 29715287

49. Mligo JB, Sindato C, Yapi BR, Mathew C, Mkupasi E, Kazwala RR, et al. Frontline health workers’ awareness and use of E-based technology to enhance reporting of human brucellosis in rural setting in Tanzania. BMC One Heal Outlook. 2021. https://doi.org/10.1186/s42522-021-00056-5 PMID: 34983693

50. Lukambagire A, Mligo J, Mwakapeje E, Mathew C, Shirima G, Karimiribó E, et al. Brucellosis Diagnosis: Performance, Reporting and Costs of Frontline Tests. Tanzania Public Heal Bull. 2021; 1: 1–31. Available: https://mcusercontent.com/00fbd4ff91363531ad64315d/files/bb6d2e60-2e2f-3e6e-b6c8-8bd91a2297bc/Lukambagire_et_al_Brucellosis_Diagnosis_TPHB_Issue_6_27_31.01.pdf.

51. Ducrotoy MJ, Muñoz PM, Conde-alvarez R, Blasco JM, Morlyón I. A systematic review of current immunological tests for the diagnosis of cattle brucellosis. Prev Vet Med. 2018; 151: 57–72. https://doi.org/10.1016/j.prevetmed.2018.01.005 PMID: 29496108

52. Ducrotoy MJ, Bardosh KL. How do you get the Rose Bengal Test at the point-of-care to diagnose brucellosis in Africa? The importance of a systems approach. Acta Trop. 2017; 165: 33–39. https://doi.org/10.1016/j.actatropica.2016.10.004 PMID: 27725154

53. Ministry of Health and Social Welfare (MoHSW) [Tanzania Mainland], Ministry of Health (MoH) [Zanzibar], (NBS) NB of S, Statistician (OCGS) O of the CG, International I. Tanzania Service Provision Assessment. Dar es Salaam; 2015. Available: https://dhsprogram.com/pubs/pdf/spa22/spa22.pdf. https://doi.org/10.1186/s12913-015-1203-7 PMID: 26634449

54. Leonard K, Masatu MC. Outpatient process quality evaluation and the Hawthorne Effect. Soc Sci Med. 2006; 63: 2330–2340. https://doi.org/10.1016/j.socscimed.2006.06.003 PMID: 16887245